12 February 2026, IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced the extension of an existing contract with one of the world’s leading international pharmaceutical companies following the continued progress of a Phase 2 clinical trial in Huntington’s Disease.
The contract extension is worth an additional c.£1.5 million in revenues to IXICO over the next three years.
Bram Goorden, CEO of IXICO, commented: "This is another example of how IXICO’s compelling IXI™ technology platform and neurological disease expertise consistently deliver gold standard outcomes for biopharma customers as they advance drug development in such a devastating neurological disease.”
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as amended by The Market Abuse (Amendment) (EU Exit) Regulations 2019. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
